Phumla Sinxadi

Switch to long-acting cabotegravir and rilpivirine in virologically suppressed adults with HIV in Africa (CARES): week 48 results from a randomised, multicentre, open-label, non-inferiority trial

HIV infection

Concentration–response relationships of dolutegravir and efavirenz with weight change after starting antiretroviral therapy

CYP2B6 Genotype and Weight Gain Differences Between Dolutegravir and Efavirenz